Prevention of artherosclerotic events in peripheral arterial disease, or within 35 days of myocardial infarction, or within 6 months of ischaemic stroke; prevention of artherosclerotic events in acute coronary syndrome without ST-segment elevation and in acute myocardial infarction with ST-segment elevation.
Dosage & Administration
Prevention of artherosclerotic events in peripheral arterial disease or after myocardial infarction or ischaemic stroke, 75 mg once daily. Acute coronary syndrome (without ST-segment elevation), initially 300 mg then 75 mg daily. Acute myocardial infarction (with ST-segment elevation), initially 300 mg then 75 mg daily; initial dose omitted if patient over 75 years.
As with the other anti-platelet agents, should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions. If a patient is to undergo elective surgery and an antiplatelet effect is not desired, Clopidogrel should be discontinued at least 7 days prior to surgery. Clopidogrel should be used with caution in patients who have lesions with a propensity to bleed (such as ulcers). Drugs that might induce such lesions (such as Aspirin and other NSAIDs should be used with caution in patients taking Clopidogrel. Clopidogrel should be used with caution in severe hepatic impaired patients. Pregnancy: There are no adequate and well-controlled studies in pregnant women. Clopidogrel should be used during pregnancy only if clearly needed. Nursing mothers: It is not known whether this drug is excreted into breast milk. Breast-feeding is not recommended while using this medicine. Pediatric use: Safety and effectiveness in the pediatric population have not been established.